Entrada Therapeutics Inc (TRDA)
15.78
-0.67
(-4.07%)
USD |
NASDAQ |
Jun 14, 16:00
15.82
+0.04
(+0.25%)
After-Hours: 20:00
Entrada Therapeutics Free Cash Flow (Quarterly): -26.36M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -26.36M |
December 31, 2023 | -4.989M |
September 30, 2023 | -25.94M |
June 30, 2023 | -36.61M |
March 31, 2023 | 201.73M |
December 31, 2022 | -28.01M |
September 30, 2022 | -28.29M |
Date | Value |
---|---|
June 30, 2022 | -18.78M |
March 31, 2022 | -21.58M |
December 31, 2021 | -21.86M |
September 30, 2021 | -14.88M |
June 30, 2021 | -9.454M |
March 31, 2021 | -9.244M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-36.61M
Minimum
Jun 2023
201.73M
Maximum
Mar 2023
-3.406M
Average
-21.58M
Median
Mar 2022
Free Cash Flow (Quarterly) Benchmarks
Catalyst Pharmaceuticals Inc | 31.73M |
Vertex Pharmaceuticals Inc | 1.058B |
Sarepta Therapeutics Inc | -284.52M |
PTC Therapeutics Inc | 6.41M |
GlycoMimetics Inc | -10.52M |